Bharat Biotech International Ltd (BBIL), the developer of Covaxin, is expected to begin production at its Andharua unit near Bhubaneswar by June 2022. The state government has issued the required statutory permissions and clearances to set up the new facility that will incur Rs 300 crore.
The Hyderabad-based company will roll out 10 types of vaccines, including Covaxin at the new unit. BBIL’s vaccines include malaria, Japanese encephalitis, rotavirus, pandemic influenza and drug-resistant staphylococcus aureus, and rabies.
Also read: Bharat Biotech: Maximum Price for Covaxin required to Recover Costs
Suresh Mahapatra, Odisha Chief Secretary, directed the state government officials to speed up the construction for starting the production by June next year during an E-meeting of state-level biotech implementation committee.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!
